Literature DB >> 24482230

Structural insights into the interaction between a potent anti-inflammatory protein, viral CC chemokine inhibitor (vCCI), and the human CC chemokine, Eotaxin-1.

Nai-Wei Kuo1, Yong-Guang Gao, Megan S Schill, Nancy Isern, Cynthia M Dupureur, Patricia J Liwang.   

Abstract

Chemokines play important roles in the immune system, not only recruiting leukocytes to the site of infection and inflammation but also guiding cell homing and cell development. The soluble poxvirus-encoded protein viral CC chemokine inhibitor (vCCI), a CC chemokine inhibitor, can bind to human CC chemokines tightly to impair the host immune defense. This protein has no known homologs in eukaryotes and may represent a potent method to stop inflammation. Previously, our structure of the vCCI·MIP-1β (macrophage inflammatory protein-1β) complex indicated that vCCI uses negatively charged residues in β-sheet II to interact with positively charged residues in the MIP-1β N terminus, 20s region and 40s loop. However, the interactions between vCCI and other CC chemokines have not yet been fully explored. Here, we used NMR and fluorescence anisotropy to study the interaction between vCCI and eotaxin-1 (CCL11), a CC chemokine that is an important factor in the asthma response. NMR results reveal that the binding pattern is very similar to the vCCI·MIP-1β complex and suggest that electrostatic interactions provide a major contribution to binding. Fluorescence anisotropy results on variants of eotaxin-1 further confirm the critical roles of the charged residues in eotaxin-1. In addition, the binding affinity between vCCI and other wild type CC chemokines, MCP-1 (monocyte chemoattractant protein-1), MIP-1β, and RANTES (regulated on activation normal T cell expressed and secreted), were determined as 1.1, 1.2, and 0.22 nm, respectively. To our knowledge, this is the first work quantitatively measuring the binding affinity between vCCI and multiple CC chemokines.

Entities:  

Keywords:  Anti-inflammatory Protein; Biophysics; Chemokine-binding Protein; Chemokines; Eotaxin; Fluorescence Anisotropy; Molecular Docking; NMR; Protein-Protein Interactions; vCCI

Mesh:

Substances:

Year:  2014        PMID: 24482230      PMCID: PMC3945322          DOI: 10.1074/jbc.M113.538991

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  VADAR: a web server for quantitative evaluation of protein structure quality.

Authors:  Leigh Willard; Anuj Ranjan; Haiyan Zhang; Hassan Monzavi; Robert F Boyko; Brian D Sykes; David S Wishart
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

2.  Using NMRView to visualize and analyze the NMR spectra of macromolecules.

Authors:  Bruce A Johnson
Journal:  Methods Mol Biol       Date:  2004

Review 3.  Chemokines and their receptors in the pathogenesis of allergic asthma: progress and perspective.

Authors:  Leslie R Bisset; Peter Schmid-Grendelmeier
Journal:  Curr Opin Pulm Med       Date:  2005-01       Impact factor: 3.155

4.  Identification by NMR of the binding surface for the histidine-containing phosphocarrier protein HPr on the N-terminal domain of enzyme I of the Escherichia coli phosphotransferase system.

Authors:  D S Garrett; Y J Seok; A Peterkofsky; G M Clore; A M Gronenborn
Journal:  Biochemistry       Date:  1997-04-15       Impact factor: 3.162

5.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

Review 6.  Targeting chemokine receptors in allergic disease.

Authors:  James E Pease
Journal:  Biochem J       Date:  2011-02-15       Impact factor: 3.857

Review 7.  Chemokines in asthma: cooperative interaction between chemokines and IL-13.

Authors:  Nives Zimmermann; Gurjit Khurana Hershey; Paul S Foster; Marc E Rothenberg
Journal:  J Allergy Clin Immunol       Date:  2003-02       Impact factor: 10.793

Review 8.  Chemokines in cancer.

Authors:  Alain P Vicari; Christophe Caux
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

9.  Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2.

Authors:  S Hemmerich; C Paavola; A Bloom; S Bhakta; R Freedman; D Grunberger; J Krstenansky; S Lee; D McCarley; M Mulkins; B Wong; J Pease; L Mizoue; T Mirzadegan; I Polsky; K Thompson; T M Handel; K Jarnagin
Journal:  Biochemistry       Date:  1999-10-05       Impact factor: 3.162

10.  Structural basis of chemokine sequestration by a tick chemokine binding protein: the crystal structure of the complex between Evasin-1 and CCL3.

Authors:  João M Dias; Christophe Losberger; Maud Déruaz; Christine A Power; Amanda E I Proudfoot; Jeffrey P Shaw
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more
  4 in total

1.  Identification of the pharmacophore of the CC chemokine-binding proteins Evasin-1 and -4 using phage display.

Authors:  Pauline Bonvin; Steven M Dunn; François Rousseau; Douglas P Dyer; Jeffrey Shaw; Christine A Power; Tracy M Handel; Amanda E I Proudfoot
Journal:  J Biol Chem       Date:  2014-09-29       Impact factor: 5.157

2.  Biophysical and Computational Studies of the vCCI:vMIP-II Complex.

Authors:  Anna F Nguyen; Nai-Wei Kuo; Laura J Showalter; Ricardo Ramos; Cynthia M Dupureur; Michael E Colvin; Patricia J LiWang
Journal:  Int J Mol Sci       Date:  2017-08-16       Impact factor: 5.923

3.  Structure-guided engineering of tick evasins for targeting chemokines in inflammatory diseases.

Authors:  Ram Prasad Bhusal; Pramod Aryal; Shankar Raj Devkota; Rina Pokhrel; Menachem J Gunzburg; Simon R Foster; Herman D Lim; Richard J Payne; Matthew C J Wilce; Martin J Stone
Journal:  Proc Natl Acad Sci U S A       Date:  2022-03-01       Impact factor: 12.779

Review 4.  The binding and specificity of chemokine binding proteins, through the lens of experiment and computation.

Authors:  Lauren E Stark; Wenyan Guan; Michael E Colvin; Patricia J LiWang
Journal:  Biomed J       Date:  2021-07-24       Impact factor: 7.892

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.